NZ597511A - Diazahomoadamantane derivatives and methods of use thereof - Google Patents
Diazahomoadamantane derivatives and methods of use thereofInfo
- Publication number
- NZ597511A NZ597511A NZ597511A NZ59751110A NZ597511A NZ 597511 A NZ597511 A NZ 597511A NZ 597511 A NZ597511 A NZ 597511A NZ 59751110 A NZ59751110 A NZ 59751110A NZ 597511 A NZ597511 A NZ 597511A
- Authority
- NZ
- New Zealand
- Prior art keywords
- diazatricyclo
- disorder
- undecane
- acetylcholine receptor
- nicotinic acetylcholine
- Prior art date
Links
- 108700006085 alpha7 Nicotinic Acetylcholine Receptor Proteins 0.000 abstract 2
- 230000006735 deficit Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 108010052671 nicotinic receptor alpha4beta2 Proteins 0.000 abstract 2
- QZFQDVLIAQNSLM-UHFFFAOYSA-N 1,4-diazatricyclo[4.3.1.13,8]undecan-4-yl(thieno[2,3-c]pyridin-5-yl)methanone Chemical compound C=1C=2C=CSC=2C=NC=1C(=O)N1CC(C2)CN3CC1CC2C3 QZFQDVLIAQNSLM-UHFFFAOYSA-N 0.000 abstract 1
- HTIKEGIKZQYHTO-UHFFFAOYSA-N 2-(1,4-diazatricyclo[4.3.1.13,8]undecan-4-yl)-5-phenyl-1,3,4-oxadiazole Chemical compound C1C(C2)CC3CN2CC1CN3C(O1)=NN=C1C1=CC=CC=C1 HTIKEGIKZQYHTO-UHFFFAOYSA-N 0.000 abstract 1
- XGYFUALJXMFBSC-UHFFFAOYSA-N 4-[5-(4-fluorophenyl)-1,3-thiazol-2-yl]-1,4-diazatricyclo[4.3.1.13,8]undecane Chemical compound C1=CC(F)=CC=C1C1=CN=C(N2C3CC4CC(CN(C4)C3)C2)S1 XGYFUALJXMFBSC-UHFFFAOYSA-N 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- QMKNDDIPPJRAOJ-UHFFFAOYSA-N N-[3-(1,4-diazatricyclo[4.3.1.13,8]undecane-4-carbonyl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC(C(=O)N2C3CC4CC(CN(C4)C3)C2)=C1 QMKNDDIPPJRAOJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000029726 Neurodevelopmental disease Diseases 0.000 abstract 1
- 102000047725 alpha7 Nicotinic Acetylcholine Receptor Human genes 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21847909P | 2009-06-19 | 2009-06-19 | |
| PCT/CN2010/000889 WO2010145208A1 (en) | 2009-06-19 | 2010-06-18 | Diazahomoadamantane derivatives and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ597511A true NZ597511A (en) | 2014-01-31 |
Family
ID=43354879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ597511A NZ597511A (en) | 2009-06-19 | 2010-06-18 | Diazahomoadamantane derivatives and methods of use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8846661B2 (https=) |
| EP (1) | EP2443122B1 (https=) |
| JP (1) | JP2012530084A (https=) |
| KR (1) | KR20120044978A (https=) |
| CN (1) | CN102459268A (https=) |
| AU (1) | AU2010262643B2 (https=) |
| BR (1) | BRPI1015043A2 (https=) |
| CA (1) | CA2765466A1 (https=) |
| IL (2) | IL216883A (https=) |
| MX (1) | MX2011014019A (https=) |
| NZ (1) | NZ597511A (https=) |
| PE (1) | PE20121066A1 (https=) |
| RU (2) | RU2549551C2 (https=) |
| SG (1) | SG176921A1 (https=) |
| WO (1) | WO2010145208A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012024615A1 (en) * | 2010-08-20 | 2012-02-23 | Research Triangle Institute | Nicotinic receptor compounds |
| CN103087001A (zh) * | 2011-11-03 | 2013-05-08 | 南京大学 | 香草酸的1，3，4-噁二唑衍生物及其制法和用途 |
| US10301294B2 (en) | 2013-03-13 | 2019-05-28 | The Broad Institute Inc. | Compounds for the treatment of tuberculosis |
| RU2552649C1 (ru) * | 2013-12-13 | 2015-06-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) | Душистые 5-бензил-1,3-диазаадамантан-6-оны |
| WO2015103005A1 (en) * | 2014-01-03 | 2015-07-09 | Research Institute At Nationwide Children's Hospital | Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers |
| WO2016100184A1 (en) | 2014-12-16 | 2016-06-23 | Forum Pharmaceuticals, Inc. | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
| MX2017016231A (es) | 2015-06-10 | 2018-11-29 | Axovant Sciences Gmbh | Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina. |
| WO2017027600A1 (en) | 2015-08-12 | 2017-02-16 | Forum Pharmaceuticals, Inc. | GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| WO2019155468A1 (en) * | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4557865A (en) * | 1984-05-07 | 1985-12-10 | Pennwalt Corporation | Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds |
| EE03566B1 (et) * | 1995-11-02 | 2001-12-17 | Neurosearch A/S | Kondenseerunud tropaanderivaadid, nende valmistamine ja kasutamine |
| TR200100462T2 (tr) * | 1998-08-18 | 2001-09-21 | Ucb, S.A. | Muskarinik agonistleri ve antagonistleri |
| CN1332726A (zh) * | 1998-11-02 | 2002-01-23 | 卫福有限公司 | 吡咯烷化合物及其药物用途 |
| BR0210391A (pt) * | 2001-06-12 | 2004-06-15 | Elan Pharm Inc | Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto |
| US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| ATE363484T1 (de) * | 2003-09-26 | 2007-06-15 | Astrazeneca Ab | Nichtamidnonane |
| US8314119B2 (en) * | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| TW200840569A (en) * | 2007-03-13 | 2008-10-16 | Targacept Inc | Sub-type selective amides of diazabicycloalkanes |
| MX2009010175A (es) * | 2007-03-23 | 2009-10-12 | Abbott Lab | Derivados de acetamida y carboxamida de aza-adamantano y metodos de uso de los mismos. |
| ATE509931T1 (de) * | 2007-03-23 | 2011-06-15 | Abbott Lab | Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür |
| CA2679885A1 (en) * | 2007-03-23 | 2008-10-02 | Abbott Laboratories | Aminomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs) |
| WO2011030349A1 (en) * | 2009-09-14 | 2011-03-17 | Suven Life Sciences Limited | L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands |
-
2010
- 2010-06-18 PE PE2011002111A patent/PE20121066A1/es not_active Application Discontinuation
- 2010-06-18 MX MX2011014019A patent/MX2011014019A/es active IP Right Grant
- 2010-06-18 CA CA2765466A patent/CA2765466A1/en not_active Abandoned
- 2010-06-18 JP JP2012515322A patent/JP2012530084A/ja not_active Ceased
- 2010-06-18 RU RU2012101784/04A patent/RU2549551C2/ru not_active IP Right Cessation
- 2010-06-18 NZ NZ597511A patent/NZ597511A/en not_active IP Right Cessation
- 2010-06-18 RU RU2015110025/04A patent/RU2015110025A/ru not_active Application Discontinuation
- 2010-06-18 WO PCT/CN2010/000889 patent/WO2010145208A1/en not_active Ceased
- 2010-06-18 SG SG2011094141A patent/SG176921A1/en unknown
- 2010-06-18 EP EP10788604.6A patent/EP2443122B1/en not_active Not-in-force
- 2010-06-18 BR BRPI1015043A patent/BRPI1015043A2/pt not_active IP Right Cessation
- 2010-06-18 AU AU2010262643A patent/AU2010262643B2/en not_active Ceased
- 2010-06-18 KR KR1020127001339A patent/KR20120044978A/ko not_active Withdrawn
- 2010-06-18 CN CN2010800368013A patent/CN102459268A/zh active Pending
- 2010-06-18 US US12/818,764 patent/US8846661B2/en not_active Expired - Fee Related
-
2011
- 2011-12-08 IL IL216883A patent/IL216883A/en not_active IP Right Cessation
-
2015
- 2015-01-21 IL IL236830A patent/IL236830A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010262643B2 (en) | 2015-02-19 |
| EP2443122A1 (en) | 2012-04-25 |
| IL236830A0 (en) | 2015-03-31 |
| IL216883A (en) | 2015-02-26 |
| RU2015110025A (ru) | 2015-08-20 |
| RU2549551C2 (ru) | 2015-04-27 |
| CA2765466A1 (en) | 2010-12-23 |
| AU2010262643A1 (en) | 2012-02-02 |
| SG176921A1 (en) | 2012-01-30 |
| BRPI1015043A2 (pt) | 2019-07-09 |
| JP2012530084A (ja) | 2012-11-29 |
| RU2012101784A (ru) | 2013-07-27 |
| CN102459268A (zh) | 2012-05-16 |
| PE20121066A1 (es) | 2012-09-13 |
| US8846661B2 (en) | 2014-09-30 |
| MX2011014019A (es) | 2012-02-22 |
| EP2443122A4 (en) | 2012-12-19 |
| WO2010145208A1 (en) | 2010-12-23 |
| US20100324027A1 (en) | 2010-12-23 |
| KR20120044978A (ko) | 2012-05-08 |
| EP2443122B1 (en) | 2014-03-05 |
| IL216883A0 (en) | 2012-02-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ597511A (en) | Diazahomoadamantane derivatives and methods of use thereof | |
| NO20091478L (no) | Aminometyl-4-imidazoler | |
| NZ592792A (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| JP2007510689A5 (https=) | ||
| NO20082059L (no) | Ny polymorf form og den amorfe formen av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid | |
| JP2008540637A5 (https=) | ||
| JP2008539195A5 (https=) | ||
| CN109153649A (zh) | 烟碱乙酰胆碱受体的变构调节剂 | |
| ATE486601T1 (de) | Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen | |
| JP2008539195A (ja) | 新規のオキサジアゾール誘導体及びそれらの医学的使用 | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| RU2012102908A (ru) | Азаадамантановые производные и способы применения | |
| JP2009520685A5 (https=) | ||
| RU2010130175A (ru) | Производные бензотиазола и бензоксазола и способы их применения | |
| WO2008155572A3 (en) | Fused quinoline derivatives useful as gaba modulators | |
| DK2358680T3 (da) | Faste former af n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluormethyl)phenyl)-3-oxo-5-(trifluormethyl)-1,4-dihydroquinolin-3-carboxamid | |
| IL295076B2 (en) | Piperidinone derivatives as MDM2 inhibitors for cancer treatment | |
| NZ596753A (en) | Phenoxymethyl heterocyclic compounds | |
| ZA201302480B (en) | Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders | |
| AU2009336839A8 (en) | Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof | |
| WO2013186792A3 (en) | Process for preparation of azilsartan medoxomil and its salts | |
| NO20075022L (no) | (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav | |
| JP2009528284A5 (https=) | ||
| RU2011136821A (ru) | Дигидрохинолиноновые производные | |
| NO20061137L (no) | Cyklopropylderivater som NK3-reseptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ABBVIE INC., US Effective date: 20130801 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 JUN 2017 BY THOMSON REUTERS Effective date: 20140619 |
|
| LAPS | Patent lapsed |